Pharmacokinetics and Dialyzability of a Single Oral Dose of Amenamevir, an Anti-Herpes Drug, in Hemodialysis Patients

ConclusionThere were no clinically relevant safety concerns when 400  mg of amenamevir was administered as a single dose to hemodialysis patients without dose adjustment and/or modification of the dosing schedule.Trial RegistrationJapicCTI-184242.

Source: Advances in Therapy - May 20, 2020 Category: Drugs & Pharmacology Source Type: research